Immutep Limited
Immutep Limited (IMMP) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IMMP · as of Jun 9, 2026
Key Statistics
Explore Immutep Limited Data
immp stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 4 · Buy rate: 50.0%
The IMMP analyst consensus is Buy, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month price target is $4.25, representing +1052.07% upside from the current price of $0.37.
Competitors & Peers
immp competitorsIMMP
ACHV
ALLO
CABA
CADL
CAPRStock Performance
Full HistoryAbout Immutep Limited
Immutep Limited is a biotechnology enterprise focused on the exploration and advancement of medicinal candidates. The company specializes in creating immunotherapeutic solutions for treating both canc…
what is immutep limited · immp stock overview · immutep limited company profile · who is immutep limited ceo · immp NASDAQ · immutep limited headquarters · immutep limited business segments
About Stock Overview & Key Data
Immutep Limited (IMMP) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 19, 2012. As of the latest trading session, IMMP stock price is $0.37, with a market capitalization of $54.4M. The stock has returned -79.95% over the past 12 months and -87.10% year-to-date.
According to 4 Wall Street analysts, the consensus rating for Immutep Limited stock is Buy, with an average 12-month price target of $4.25. In fiscal year 2025, Immutep Limited reported revenue of $5.0M and net income of -$61.4M. For detailed data — including Immutep Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Immutep Limited (IMMP) stock price is $0.37. The stock is traded on NASDAQ under the ticker symbol IMMP. The 52-week range is $0.29 – $3.53.